Summary: Hims & Hers Health said second-quarter revenue topped estimates and the company subsequently boosted its annual revenue guidance after reporting subscriber growth and increased platform engagement tied to expanded personalized care offerings, including branded weight-loss drug availability.
Hims & Hers Health on Monday disclosed second-quarter results that exceeded market forecasts and prompted the company to raise its revenue target for the year. Management attributed the upside to higher subscriber counts and growth in personalized healthcare services offered through its telehealth platform.
In the quarter, the company recorded revenue of $753 million, up from $544 million a year earlier. Analysts polled by LSEG had forecast revenue of $699.89 million. Following the stronger performance, Hims & Hers lifted its full-year revenue guidance to a range of $3.1 billion to $3.3 billion, up from the prior forecast of $2.8 billion to $3.0 billion.
Hims & Hers has shifted its product mix during the year, moving toward offering branded, FDA-approved weight-loss medications on its platform. The company said this pivot to branded treatments - including the rollout of a blockbuster weight-loss drug through a partnership announced in March - helped increase user engagement and traffic across its services.
Earlier this year, Hims & Hers signaled a change in strategy by moving away from lower-cost compounded GLP-1 treatments that had previously supported growth and instead focusing on branded versions of these therapies. In March, the company announced a partnership with the drugmaker to make a leading prescription weight-loss medication available on its platform. That arrangement followed regulatory action to restrict copycat weight-loss drugs and resolved a prior legal dispute between the companies.
Company executives and investors pointed to the combination of rising subscriber numbers and expanded branded treatment availability as the key drivers of the quarter’s stronger-than-expected top-line performance. The updated guidance reflects management’s view of continued revenue momentum for the remainder of the year.
While the company emphasized subscriber growth and personalized healthcare offerings as performance catalysts, its strategic shift from compounded GLP-1 products to branded medications and the timing of partnerships and regulatory developments played a central role in recent platform activity and engagement.
Key points
- Hims & Hers reported Q2 revenue of $753 million, versus $544 million a year earlier, beating analyst expectations of $699.89 million.
- The company raised full-year revenue guidance to $3.1 billion - $3.3 billion from the prior $2.8 billion - $3.0 billion range.
- Growth was driven by increased subscribers and expanded personalized healthcare offerings, including a move toward branded FDA-approved weight-loss drugs offered via a partnership announced in March.
Sectors impacted: telehealth, digital healthcare services, and the broader pharmaceutical distribution channel via online platforms.
Risks and uncertainties
- Regulatory actions: The FDA’s restrictions on copycat weight-loss drugs influenced product availability and partnership dynamics, indicating regulatory developments can materially affect the company’s offerings and platform activity - impacting the telehealth and pharmaceutical sectors.
- Subscriber growth dependency: The company’s improved results hinge on continued subscriber growth and engagement; any slowdown in subscriber additions could affect revenue momentum - relevant to digital health and subscription-based care models.